Reversal of multi-drug resistance by vector-based-ShRNA-Mdr1 In Vitro and In Vivo

Abstract

In order to investigate the effects of vector-based hairpin small interference RNA (shRNA) on the reversal of multi-drug resistance (mdr) of A2780/Taxol cells, a novel vector pEGFP-H1/mdr1 containing mdr1-shRNA targeting at position 2943–2963 of mdr1 was designed and synthesized. Subsequently, A2780/Taxol cells were transfected with pEGFP-H1/mdr1, and the expression of mdr1 mRNA and P-gp was detected by using RT-PCR and Western blot respectively. MTT was used to measure the 50% inhibition concentration (IC₅₀) of Taxol to A2780/Taxol cells. The results showed that at the 24th and 48th h after transfection, the expression of mdr1 mRNA was decreased to (52.1±1.0)% and (0.01±1.7)%, and that of P-gp decreased to (88.3±2.1)% and 0%, respectively. At the 48th h after transfection, the relative reversal rate of A2780/Taxol cells to Taxol was 69.54%. In vivo, the nude mice xenografts were injected with pEGFP-H1/mdr1, and then administrated Taxol. The tumor volume in pEGFP-H1/mdr1-transfected group was significantly reduced as compared with that in blank control group or pEGFP-H1-transfected group (807.20±103.16 vs 1563.78±210.54 or 1480.78±241.24 mm³, both P<0.01). These results suggested that transfection of pEGFP-H1/mdr1 could efficiently down-regulate the expression of mdr1 mRNA and P-gp in A2780/Taxol cells, and effectively restore the sensitivity of A2780/Taxol cells to Taxol both in vitro and in vivo.

Keywords

RNA interference / multi-drug resistance / gene therapy

References

[1] ThomasH., ColeyH.M.. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control, 2003, 10(2): 159-165

[2] LooT.W., ClarkeD.M.. Recent progress in understanding the mechanism of P-glycoprotein-mediated drug efflux. J Membr Biol, 2005, 206(3): 173-185

[3] YusufR.Z., DuanZ., LamendolaD.E., et al.. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets, 2003, 3(1): 1-19

[4] RoninsonI.B., ChinJ.E., ChoiK.G., et al.. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA, 1986, 83(12): 4538-4542

[5] MasanekU., StammlerG., VolmM.. Modulation of multidrug resistance in human ovarian cancer cell lines by inhibition of P-glycoprotein 170 and PKC isoenzymes with antisense oligonucleotides. J Exp Ther Oncol, 2002, 2(1): 37-41

[6] NagataJ., KijimaH., HatanakaH., et al.. Reversal of drug resistance using hammerhead ribozymes against multidrug resistance-associated protein and multidrug resistance 1 gene. Int J Oncol, 2002, 21(5): 1021-1026

[7] RamachandranC., WellhamL.L.. Effect of MDR1 phosphorothioate antisenseoligodeoxynucleotides in multidrug-resistant human tumor cell lines and xenografts. Anticancer Res, 2003, 23(3B): 2681-2690

[8] NiethC., PriebschA., StegeA., et al.. Modulation of the classical multidrug resistance (MDR) phenotype by RNA interference (RNAi). FEBS Lett, 2003, 545(2–3): 144-150

[9] HannonG.J., RossiJ.J.. Unlocking the potential of the human genome with RNA interference. Nature, 2004, 431(7006): 373-378

[10] LuanY.Z., LiL., LiD., et al.. Development of five kinds of drug-resistant ovarian cancer cell lines and expression of partial resistance-related genes. Chin J Obstet Gynecol (Chinese), 2004, 39(6): 403-407

[11] GottesmanM.M., FojoT., BatesS.E.. Multidrug resistance in cancer: Role of ATP-dependent transporters. Nat Rev Cancer, 2002, 2(1): 48-58

[12] SchwarzD.S., HutvagnerG., DuT., et al.. Asymmetry in the assembly of the RNAi enzyme complex. Cell, 2003, 115(2): 199-208

[13] LageH.. MDR1/P-glycoprotein (ABCB1) as target for RNA interference-mediated reversal of multidrug resistance. Curr Drug Targets, 2006, 7(7): 813-821

[14] MatsukuraS., JonesP.A., TakaiD.. Establishment of conditional vectors for hairpin siRNA knockdowns. Nucl Acids Res, 2003, 31(15): e77

[15] StevensonM.. Therapeutic potential of RNA interference. N Engl J Med, 2004, 351(17): 1772-1777

[16] SuiG., SoohooC., AffarE.I.B., et al.. A DNA vector based RNAi technology to suppress gene expression in mammalian cells. PNAS, 2002, 99(8): 5515-5520

[17] ElbashirS.M., LendeckelW., TuschlT.. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev, 2001, 15(2): 188-200

[18] LuS., WangX., CaiL., et al.. Inhibition of MDR1 gene by hairpin siRNA to reversal of multi-drug resistance in ovarian cancer cells. Chin J Obstet Gynecol (Chinese), 2007, 42(4): 60-62

[19] PanG.D., YangJ.Q., YanL.N., et al.. Reversal of multi-drug resistance by pSUPER-shRNA-mdr1 in vivo and in vitro. World J Gastroenterol, 2009, 15(4): 431-440

[20] SteinU., WaltherW., StegeA., et al.. Complete in vivo reversal of the multidrug resistance phenotype by Jet-injection of anti-MDR1 short hairpin RNA-encoding plasmid DNA. Molecular Therapy, 2008, 16(1): 178-186

[21] LuS., WangX., XiaoL., et al.. Gene therapy for ovarian cancer using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene directed by MDR1 promoter. Cancer Biology Therapy, 2007, 6(3): 397-404

[22] YangY., WangZ., LiM., et al.. Chitosan/pshRNA plasmid nanoparticles targeting MDR1 gene reverse paclitaxel resistance in ovarian cancer cells. J Huazhong Univ Sci Technolog Med Sci, 2009, 29(2): 239-242